January 8-10, 2026 | San Francisco, CA
Quest Diagnostics® booth 73
We’re excited to participate in the American Society of Clinical Oncology (ASCO®) Gastrointestinal (GI) Cancers Symposium, where leading experts will gather to advance care for GI malignancies through science and collaboration.
We invite you to stop by Quest Diagnostics® booth 73 to learn how Haystack MRD®’s exceptionally accurate ctDNA testing brings confidence to residual disease detection, treatment monitoring, and recurrence detection in GI cancers.
Whether you’re focused on colorectal, gastric, pancreatic, or other GI tumor types, Haystack MRD offers
- Ultradeep sequencing that reads each molecule up to 1 million times
- Patented error-correction technology that ensures each variant is present on both DNA strands
- Exceptional sensitivity and specificity
- Confident MRD results for adjuvant decisions, treatment monitoring, and surveillance
- Clinical trial support including patient enrichment and stratification
- The power of Quest for a streamlined ordering process and accessibility
See our latest clinical data
We are proud to present 2 posters at the symposium with new evidence supporting the performance and clinical utility of Haystack MRD in GI cancers:
Title: Reproducibility and clinical concordance of a tumor-informed MRD assay in patients with resected colorectal cancer from the DYNAMIC trials
Abstract number: 26
Session time and date: January 10, 12:00 PM–1:30 PM (PST)
This retrospective analysis of samples from the DYNAMIC and DYNAMIC-III trials reinforce Haystack MRD as a robust tool for adjuvant therapy decision-making, demonstrating
- 100% interlaboratory concordance
- High sensitivity and specificity for recurrence detection in stage II/III CRC
- Strong correlation between ctDNA status and clinical outcomes
Title: Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC)
Abstract number: 30
Session time and date: January 10, 12:00 PM–1:30 PM (PST)
Early findings from the ongoing prospective study
- Excellent ctDNA detection sensitivity both pre-treatment and at 6 months
- Sensitivity of ctDNA detection was improved compared to previous reports
- Strong prognostic value for identifying relapse risk
Let’s connect in San Francisco.
Visit booth 73 to see how Haystack MRD is reshaping precision oncology through ctDNA insights.
